Global initiative for chronic obstructive lung disease stage 0 is associated with excess FEV1 decline in a representative population sample

Chest

Volumn 138, Issue 3, 2010, Pages 605-613

  Brito Mutunayagam, Roshan ^a   Appleton, Sarah L ^b   Wilson, David H ^b   Ruffin, Richard E ^b   Adams, Robert J ^b  

^a Queensland Government   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT;

ADULT; AGE DISTRIBUTION; AGED; AIRWAY OBSTRUCTION; ANTHROPOMETRY; ARTICLE; ASTHMA; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; COUGHING; DEPRESSION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORBIDITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; SENSITIVITY ANALYSIS; SMOKING; SMOKING CESSATION; SPIROMETRY; SPUTUM; COMPLICATION; HEALTH STATUS; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTIVE VALUE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; COHORT STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 77956821892     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-2607     Document Type: Article

References (39)

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, NHLBI/WHO Workshop Report. Bethesda, MD: National Institutes of Health, NHLBI; 2001. Publication 2701.
2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. (Updated 2009). http://www.goldcopd.com/GuidelinesResources.asp?l1= 2&l2=0. Accessed April 23, 2010.
3. Vestbo J, Lange P. Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med. 2002;166(3):329-332.
4. Stavem K, Sandvik L, Erikssen J. Can Global Initiative for Chronic Obstructive Lung Disease stage 0 provide prognostic information on long-term mortality in men? Chest. 2006;130(2):318-325. (Pubitemid 44266996)
5. de Marco R, Accordini S, Cerveri I, et al. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med. 2007;175(1):32-39.
6. de Marco R, Accordini S, Cerveri I, et al; European Community Respiratory Health Survey Study Group. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax. 2004;59(2):120-125.
7. Lindberg A, Eriksson B, Larsson L-G, Rönmark E, Sandström T, Lundbäck B. Seven-year cumulative incidence of COPD in an age-stratified general population sample. Chest. 2006;129(4):879-885.
8. Lindberg A, Jonsson A-C, Rönmark E, Lundgren R, Larsson LG, Lundbäck B. Ten-year cumulative incidence of COPD and risk factors for incident disease in a symptomatic cohort. Chest. 2005;127(5):1544-1552.
9. Ekberg-Aronsson M, Pehrsson K, Nilsson J-A, Nilsson PM, Löfdahl CG. Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir Res. 2005;6:98.
10. Mannino DM. GOLD stage 0 COPD: is it real? Does it matter? Chest. 2006;130(2):309-310.
11. Sterk PJ. Let's not forget: the GOLD criteria for COPD are based on post-bronchodilator FEV1. Eur Respir J. 2004;23(4):497-498.
12. Grant JF, Chittleborough CR, Taylor AW, et al; North West Adelaide Health Study Team. The North West Adelaide Health Study: detailed methods and baseline segmentation of a cohort for selected chronic diseases. Epidemiol Perspect Innov. 2006;3:4.
13. Taylor AW, Wilson DH, Wakefield M. Differences in health estimates using telephone and door-to-door survey methods - a hypothetical exercise. Aust N Z J Public Health. 1998;22(2):223-226. (Pubitemid 28175070)
14. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. http://www.idf.org/metabolic-syndrome. Accessed April 23, 2010.
15. Ruffin RE, Wilson DH, Chittleborough CR, Southcott AM, Smith B, Christopher DJ. Multiple respiratory symptoms predict quality of life in chronic lung disease: a population-based study of Australian adults. Qual Life Res. 2000;9(9):1031-1039.
16. Selim AJ, Ren XS, Fincke G, Rogers W, Lee A, Kazis L. A symptom-based measure of the severity of chronic lung disease: results from the Veterans Health Study. Chest. 1997;111(6):1607-1614.
17. Radloff L. The CES-D scale: A self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385-401.
18. Ware J, Snow K, Kosinski M, et al. SF-36 health survey: manual and interpretation guide. Boston, MA: The Health Institute, New England Medical Center; 1993.
19. Wilson D, Parsons J, Tucker G. The SF-36 summary scales: problems and solutions. Soz Praventivmed. 2000;45(6):239-246. (Pubitemid 32051442)
20. American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med. 1995;152(3):1107-1136.
21. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med. 2002;166(5):675-679.
22. Han MK, Postma D, Mannino DM, et al. Gender and chronic obstructive pulmonary disease: why it matters. Am J Respir Crit Care Med. 2007;176(12):1179-1184.
23. Camp PG, O'Donnell DE, Postma DS. Chronic obstructive pulmonary disease in men and women: myths and reality. Proc Am Thorac Soc. 2009;6(6):535-538.
24. Carrasco-Garrido P, de Miguel-Díez J, Rejas-Gutierrez J, et al. Characteristics of chronic obstructive pulmonary disease in Spain from a gender perspective. BMC Pulm Med. 2009;9:92.
25. Becklake MR, Kauffmann F. Gender differences in airway behaviour over the human life span. Thorax. 1999;54(12):1119-1138.
26. Vestbo J, Prescott E, Lange P; Copenhagen City Heart Study Group. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Am J Respir Crit Care Med. 1996;153(5):1530-1535.
27. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest. 2002;121(5 suppl):121S-126S.
28. Gan WQ, Man SF, Postma DS, Camp P, Sin DD. Female smokers beyond the perimenopausal period are at increased risk of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Res. 2006;7:52.
29. Connett JE, Murray RP, Buist AS, et al; Lung Health Study Research Group. Changes in smoking status affect women more than men: results of the Lung Health Study. Am J Epidemiol. 2003;157(11):973-979.
30. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178(4):332-338.
31. Blanc PD, Iribarren C, Trupin L, et al. Occupational exposures and the risk of COPD: dusty trades revisited. Thorax. 2009;64(1):6-12.
32. Maleki-Yazdi MR, Lewczuk CK, Haddon JM, et al. Early detection and impaired quality of life in COPD GOLD stage 0: a pilot study. COPD. 2007;4(4):313-320.
33. Maurer J, Rebbapragada V, Borson S, et al; ACCP Workshop Panel on Anxiety and Depression in COPD. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest. 2008;134(4 suppl):43S-56S.
34. Di Marco F, Verga M, Reggente M, et al. Anxiety and depression in COPD patients: The roles of gender and disease severity. Respir Med. 2006;100(10):1767-1774.
35. Marquis K, Maltais F, Duguay V, et al. The metabolic syndrome in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil. 2005;25(4):226-232. (Pubitemid 41153761)
36. Watz H, Waschki B, Kirsten A, et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest. 2009;136(4):1039-1046.
37. Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax. 2003;58(5):388-393.
38. Buist AS, McBurnie MA, Vollmer WM, et al; BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;370(9589):741-750.
39. Guerra S, Sherrill DL, Venker C, Ceccato CM, Halonen M, Martinez FD. Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk. Thorax. 2009;64(10):894-900.